Supplementary Tables S1-S24 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort. Supplementary Table S2: Genes analyzed as part of this study. Supplementary Table S3: Prevalence of alterations in the genes analyzed. Supplementary Table S4: Prevalence of gene alterations in 81 cases with liquid biopsies. Supplementary Table S5: Chromosomal losses and gains in SCLC. Supplementary Table S6: TET2 loss of function alterations detected in SCLCs. Supplementary Table S7: Manual review of specific mutation subgroups in SCLCs. Supplementary Table S8: Patterns of gene alterations in SMARCA4 altered and wild-type tumors. Supplementary Table S9: Prevalence of gene alterations in rearrangement-positive SCLCs. Supplementary Table S10: Univariate analysis of association between gene alterations and overall surival in the clinical cohort of stage III/IV SCLC tumors. Supplementary Table S11: Patterns of tumor mutational burden based on site of biopsy. Supplementary Table 12: Summary of tumor purity and tumor mutational burden by biopsy site. Supplementary Table S13: Aneuploidy patterns based on site of biopsy. Supplementary Table S14: Comparison of gene alterations in each biopsy site against lung biopsies. Supplementary Table S15: Comparison of gene alterations in liver and brain metastases. Supplementary Table S16: Summary of PTEN alterations in brain and other biopsy sites. Supplementary Table S17: Patterns of co-occurrence and mutual exclusivity between gene alterations in the overall SCLC cohort. Supplementary Table S18: Patterns of gene alterations in TP53 and/or RB1 mutant and wild-type cohorts. Supplementary Table S19: Patterns of gene alterations in young and older patients with SCLC. Supplementary Table S20: Patterns of gene alterations in HPV positive and HPV negative tumors. Supplementary Table S21: Manual review of specific HPV+ SCLCs. Supplementary Table S22: Patterns of gene alterations in STK11 mutant and wild-type cohorts. Supplementary Table S23: Patterns of gene alterations in EGFR mutant and wild-type cohorts. Supplementary Table S24: EGFR kinase domain alterations identified in the overall SCLC cohort.